News
Biogen’s new data, presented at the Alzheimer’s Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.
FEATURED STORIES
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
As antibody-drug conjugates advance and move into earlier lines of treatment, drug developers have to build gentler therapies that don’t just extend survival but improve it.
FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.
Germany-based Evotec AG forged its third partnership in May, a deal with Spain’s Almirall S.A. to develop new therapeutics for severe diseases of the skin.
Enanta Pharmaceuticals’ attempt to find an effective treatment for respiratory syncytial virus (RSV) met a roadblock after its candidate failed to meet the primary endpoint in Phase II.
Following reports that Pfizer has declined study requests for Paxlovid, the company and NIH are said to be in conversation about potential studies assessing a longer treatment period of the antiviral.
Virongy is expanding again and has committed to a $471,000 expansion with up to 70 new jobs.
Spruce Biosciences is developing what could be the first new therapy treating congenital adrenal hyperplasia (CAH) since the 1960s, and a new therapy for women with polycystic ovary syndrome.
In a Phase IIb study, data showed that Prota Therapeutics’ oral immunotherapy led to 51% of children reaching clinical remission of their peanut allergy compared to placebo. See inside for this and more!
GeNeuro is developing therapeutics that tackle the viral proteins that potentially contribute to neurodegeneration seen in patients with MS, amyotrophic lateral sclerosis (ALS) and even COVID-19.
Flagship Pioneering announced the launch of Sonata Therapeutics. The fledgling company was created by combining two Flagship companies, Inzen Therapeutics and Cygnal Therapeutics.
Applied Molecular Transport (AMT) provided a strategy update on Wednesday. Part of the update includes reducing its workforce by about 40% and funneling resources into its lead program.